Clinical trial
A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
NCT04430842 is registered in ClinicalTrials.gov with Quadriga Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Open Label, Multi-Center, Single and Multiple Dose, Dose Escalation and Expansion Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S in Previously Treated Patients With Advanced or Metastatic Cancers With High LAT1 Signatures, and in Patients With Relapsed or Refractory Grade 4 Astrocytoma
- Lead sponsor
- Quadriga Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- July 20, 2020
- Completion date
- December 22, 2022
- Enrollment
- 15 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.
astrocytoma, bladder cancer, brain cancer, brain metastases, breast cancer, cervical cancer, cholangiocarcinoma, colorectal cancer, esophagus cancer, gastric cancer, head and neck cancer, kidney cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, pleural mesothelioma, prostate cancer, sarcoma, thymic carcinoma, tongue cancer, urinary tract cancer